A new report sets out pharma's U.S. pricing problem, and topping it off is the growing cost of access: $1,100 per capita.
GlaxoSmithKline hopes to get its new Benlysta formula under lupus patients’ skin—literally.
CAR-T and TCR therapies have seen a whirlwind few years. Is 2017 set to be the year we see a CAR-T therapy approved? On a mission to find out, we sat down with…
With early HIV vaccine results announced Monday, Johnson & Johnson and its partners hope they might have a winner.
In lowering their rating, analysts with Credit Suisse highlighted some concerns with Pfizer's business going forward.
With the expanding definition of “health” in play, does the category warrant a separate show in a program like the Lions?
U.S. Merck's shingles vaccine Zostavax faces a growing challenge in court.
Endo has decided the 350 jobs it whacked from its Huntsville, Alabama, manufacturing site were not enough and will close it instead.
Cyndi Lauper is back to star in another round of Novartis’ Cosentyx marketing. The '80s pop icon appears with two real-life patients in a new TV spot.
Corning, with input from Pfizer and Merck, intends to build a $500 million plant in the U.S. to produce a new pharma glass.
Takeda is relocating hundreds of jobs, a key Velcade patent was restored till 2022, 36 drugs were added to China's insurance drug list after huge…
AstraZeneca CEO Pascal Soriot is publicly keeping silent on last week’s report that he was bound for Teva. But not so, inside the company.